Sfoglia per AUTORE
MUSURACA G
Collezione AO Cuneo
Items : 2
End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 Ma
2024
AOU Alessandria
AO Cuneo
AOU Alessandria
AO Cuneo
Usai SV; Vitolo U; Falcinelli F; Gini G; Galimberti S; Roti G; Mannina D; Musto P; Conconi A; Massaia M; Bari A; Califano C; Arcari A; Chiarenza A; Pavone V; Bolis SAM; Bianchi B; Tosi P; Musuraca G; Ladetto M; Barbieri E; Monaco L; Franceschetto A; Peano S; Durmo R; Marcheselli L; Bergesio F; Fallanca F; Chauvie S; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...